MENU
+Compare
ATAI
Stock ticker: NASDAQ
AS OF
Jul 8, 04:59 PM (EDT)
Price
$2.63
Change
-$0.12 (-4.36%)
Capitalization
583.4M

ATAI stock forecast, quote, news & analysis

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes... Show more

ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ATAI with price predictions
Jul 07, 2025

ATAI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ATAI turned positive on July 02, 2025. Looking at past instances where ATAI's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 26, 2025. You may want to consider a long position or call options on ATAI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATAI advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 95 cases where ATAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ATAI moved out of overbought territory on July 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATAI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATAI broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.670) is normal, around the industry mean (16.718). P/E Ratio (0.000) is within average values for comparable stocks, (58.312). ATAI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.371). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (232.558) is also within normal values, averaging (263.500).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

ATAI paid dividends on August 24, 2018

ATAI Life Sciences NV ATAI Stock Dividends
А annual dividend of $1.50 per share was paid with a record date of August 24, 2018, and an ex-dividend date of August 27, 2018. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.39B. The market cap for tickers in the group ranges from 151 to 309.49B. NONOF holds the highest valuation in this group at 309.49B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 9%. For the same Industry, the average monthly price growth was 14%, and the average quarterly price growth was 13%. IUGND experienced the highest price growth at 2,586%, while MMIRF experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was 6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of computer-based testing services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Miscellaneous Commercial Services
Address
Wallstrasse 16
Phone
+49 8921539035
Employees
88
Web
https://www.atai.life